Top

Journal of Ophthalmic Inflammation and Infection

Published in:

Open Access 01-12-2016 | Letter to the Editor

Refractory necrotizing scleritis successfully treated with adalimumab

Authors: Lola E. Lawuyi, Avinash Gurbaxani

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2016

Abstract

Necrotizing scleritis is the most severe and destructive form of scleritis with vision-threatening sequelae. It is divided into with inflammation and without inflammation (scleromalacia perforans). Adalimumab is a tumour necrosis factor (TNF)-inhibiting anti-inflammatory medication licensed for the treatment of rheumatoid and psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease (in the USA). We report two cases of necrotizing scleritis successfully treated with adalimumab.

Nussenbalt RB, Whitcup SM (2010) Uveitis: fundamentals and clinical practice, 4th edn. Elsevier, Philadelphia

Garg SJ. Wills Eye Institute- Uveitis (Colour Atlas and Synopsis of Clinical Ophthalmology). Lippincott Williams & Wilkins; 2012

Di Girolamo N, Visvanathan K, Lloyd A, Wakefield D (1997) Expression of TNF-alpha by human plasma cells in chronic inflammation. J Leukoc Biol 61(6):667–678PubMed

Di Girolamo N, Lloyd A, McCluskey P, Filipic M, Wakefield D (1997) Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol 150(2):653–666PubMedPubMedCentral

Lopez Gonzalez R, Loza E, Jover JA et al (2009) Treatment for refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol 38(1):58–62CrossRefPubMed

Sen HN, Sangave A, Hammel K et al (2009) Infliximab for the treatment of active scleritis. Can J Ophthalmol 44(3):e9–e12CrossRefPubMedPubMedCentral

Ragum A, Kolomeyer AM, Fang C, Xu Y, Chu DS (2014) Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocul Immunol Inflamm 22(6):469–477CrossRef

Bawazeer AM, Raffa LH (2011) Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol 4(3):139–141CrossRefPubMedPubMedCentral

Restrepo JP, Molina MP (2010) Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 29(5):559–561CrossRefPubMed

10.

Morarji J, Joshi L, Tomkins-Netzer O, Lightman S, Taylor SRJ (2012) Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol 3:286–290CrossRefPubMedPubMedCentral

11.

Blank M, Shoenfeld Y (2007) B cell targeted therapy in autoimmunity. J Autoimmun 28:62–68CrossRefPubMed

12.

Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51(Suppl 6):vi37–vi43CrossRefPubMed

13.

Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104CrossRefPubMed

14.

Solomon AJ, Spain RI, Kruer MC et al (2011) Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 17(12):1472–1487CrossRefPubMed

15.

British Society for Rheumatology (2005) Update on the British Society for Rheumatology. Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 44(2):157–163, [Online] [Access 2015 November]. Available from URL http://rheumatology.oxfordjournals.org

Title: Refractory necrotizing scleritis successfully treated with adalimumab
Authors: Lola E. Lawuyi
Avinash Gurbaxani
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Ophthalmic Inflammation and Infection / Issue 1/2016
Electronic ISSN: 1869-5760
DOI: https://doi.org/10.1186/s12348-016-0107-y

At a glance: The STEP trials

Springer Medicine

Refractory necrotizing scleritis successfully treated with adalimumab

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Vanishing retinal arterial aneurysms with anti-tubercular treatment in a patient presenting with idiopathic retinal vasculitis, aneurysms, and neuroretinitis

Dematiaceous fungal endophthalmitis: report of a case and review of the literature

Barriers to hand hygiene in ophthalmic outpatients in Uganda: a mixed methods approach

Immune recovery uveitis in HIV patients with cytomegalovirus retinitis in the era of HAART therapy—a 5-year study from Singapore

Microbiological profiles of fungal keratitis: a 10-year study at a tertiary referral center

A national survey of Canadian ophthalmologists to determine awareness of published guidelines for the management of uveitis